Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
From the understanding of PPARγ's transcription targets in those pathways, novel hypertension therapy target(s) will emerge.
|
31789920 |
2020 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.
|
31815758 |
2020 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Recently, consistent data showed that hypoglycemic agents targeting PPARγ as well as renin⁻angiotensin system inhibitors and mineralocorticoid receptor blockers may influence pulmonary hemodynamics in different models of pulmonary hypertension.
|
30791536 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
PPAR-γ agonist, pioglitazone, reduced oxidative and endoplasmic reticulum stress associated with L-NAME-induced hypertension in rats.
|
31730865 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
PPARγ can serve as potential target in treatments of metabolic syndrome diseases and/or hypertension.
|
31184312 |
2019 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Association between peroxisome proliferator-activated receptor γ-2 gene Pro12Ala polymorphisms and risk of hypertension: an updated meta-analysis.
|
30777927 |
2019 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Therefore, we evaluate the effects of telmisartan on PPARγ protein expression, biomechanics, density and bone microarchitecture of femurs and lumbar vertebrae in SHR ovariectomized animals, a model of hypertension in which preexisting bone impairment has been demonstrated.
|
31606379 |
2019 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mice selectively expressing PPARγ dominant negative mutation in vascular smooth muscle exhibit RhoBTB1-deficiency and hypertension.
|
30896450 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Pulmonary arterial remodelling by deficiency of peroxisome proliferator-activated receptor-γ in murine vascular smooth muscle cells occurs independently of obesity-related pulmonary hypertension.
|
30813929 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
We hypothesize that endothelial PPARγ (peroxisome proliferator-activated receptor-γ) provides cardiovascular protection in offspring from pregnancies complicated by hypertension.
|
31104564 |
2019 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Mutual promotion of FGF21 and PPARγ attenuates hypoxia-induced pulmonary hypertension.
|
30714402 |
2019 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
LncRNA AK094457 promotes AngII-mediated hypertension and endothelial dysfunction through suppressing of activation of PPARγ.
|
31404524 |
2019 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Combined L-LAME and HF diet-induced hypertension is related to increased oxidative stress, inhibiting AMP-activated protein kinase (AMPK)/ peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α) pathway and altered gut microbiota compositions.
|
31108332 |
2019 |
Hypertensive disease
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Polymorphisms in both the PPARG and AGTR1 genes were found to be significantly associated with hypertension.
|
29266977 |
2018 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
In addition, a significant increase in serum levels of sCD36, PPAR-γ and YKL-40 was observed in patients with T2DM (>5 yr) with hypertension compared to healthy controls (P< 0.05).
|
29806605 |
2018 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Peroxisome proliferator activated receptor-gamma (PPAR-γ) is implicated in several metabolic syndromes including Diabetic Nephropathy, besides obesity, insulin insensitivity, dislipidemia, inflammation, and hypertension.
|
28539091 |
2018 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The interactions between PPARγ and the canonical WNT/β-catenin pathway through the regulation of the renin-angiotensin system in hypertension may be an interesting way to better understand the actions and the effects of PPARγ agonists as antihypertensive drugs.
|
29884931 |
2018 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.
|
29695452 |
2018 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
The down-regulation of peroxisome proliferator-activated receptor γ (PPARγ) expression has been found to correlate with the proliferation of pulmonary artery smooth muscle cells (PASMC), pulmonary vascular remodeling and pulmonary hypertension, while the molecular mechanisms underlying PPARγ reduction in PASMC remain largely unclear.
|
28484848 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Here we describe an inducible tissue specific KO protocol used to study the role of PPARγ in smooth muscle cells (SMC) in angiotensin (Ang) II-induced hypertension in adult mice.
|
28116732 |
2017 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Impaired PPARγ activity in endothelial cells causes oxidative stress and endothelial dysfunction which causes a predisposition to hypertension, but the identity of key PPARγ target genes that protect the endothelium remain unclear.
|
28352663 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Thus, comp#91 could be identified as a promising lead in the development of dual AT<sub>1</sub>R antagonist and PPARγ partial agonist against hypertension and type 2 diabetes.
|
27602589 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
Selective expression of dominant negative (DN) peroxisome proliferator-activated receptor γ (PPARγ) in vascular smooth muscle cells (SMC) results in hypertension, atherosclerosis, and increased nuclear factor-κB (NF-κB) target gene expression.
|
28507170 |
2017 |
Hypertensive disease
|
0.700 |
Biomarker
|
group |
BEFREE |
The biological actions of PPARα and PPARγ and their potential as a cardiovascular therapeutic target have been extensively reviewed, whereas the biological actions of PPARβ/δ and its effectiveness as a therapeutic target in the treatment of hypertension remain less investigated.
|
27881385 |
2017 |
Hypertensive disease
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Activation of PPARγ by baicalin attenuates pulmonary hypertension in an infant rat model by suppressing HMGB1/RAGE signaling.
|
28396833 |
2017 |